The Pharma Navigator• Jan 12, 2026• 6:04

J.P. Morgan Healthcare Conference 2026: Navigating New Therapeutic Frontiers

Executive Summary

The upcoming J.P.
Morgan Healthcare Conference is expected to shift focus from modality hype (like GLP-1s) to clinical validation of new mechanisms of action across the industry.
The speaker is highly bullish on targeted protein degradation, citing recent positive data and its potential to become an entirely new class of drugs for oncology and immunology.
Gene editing and gene writing are identified as foundational future technologies, with tissue-specific delivery beyond the liver being the critical challenge to unlock their full potential.
CAR-T cell therapies are poised for significant expansion beyond oncology into immunological and autoimmune diseases, with in vivo approaches seen as key to improving scalability and accessibility.

7 quotes

Concerns Raised

Achieving tissue-specific drug delivery beyond the liver for genetic medicines.
Current scalability and accessibility limitations of ex vivo cell therapies.

Opportunities Identified

Targeted protein degradation emerging as a completely new class of drugs.
Expansion of CAR-T therapies into the large autoimmune and immunological disease markets.
In vivo CAR-T approaches dramatically improving the scalability and accessibility of cell therapy.
Gene editing and writing becoming foundational capabilities for the entire industry.

Key Themes

Shift from Hype to Clinical Validation

The speaker predicts the 2024 J.P. Morgan conference will be defined by tangible clinical data and proof-of-concept for new mechanisms, rather than a single dominant therapeutic modality like GLP-1s in the prior year. This reflects a maturing industry focus on execution and evidence-based confidence.

This signals a healthier, more fundamentally-driven investment environment where companies with strong clinical results will be rewarded over those with speculative platforms.

The Rise of Targeted Protein Degradation (TPD)

High conviction is expressed for TPD as a potential new class of drugs. Recent encouraging data from companies like Kymera Therapeutics on its STAT6 degrader is highlighted as evidence of the modality's promise to tackle difficult targets and overcome resistance.

TPD represents a significant new frontier in drug development, creating major investment and partnership opportunities and offering novel therapeutic strategies for a range of diseases.

Advancements in Genetic Medicines and Delivery

Gene editing and gene writing are viewed as foundational future capabilities for the industry. The primary bottleneck and area of focus is achieving tissue-specific delivery beyond the liver, with both viral vectors and next-generation platforms showing promise.

Solving the extra-hepatic delivery challenge will dramatically expand the addressable market for genetic medicines, enabling precise treatment for a much wider array of genetic diseases.

CAR-T Expansion Beyond Oncology

The speaker sees significant potential for CAR-T cell therapies to move beyond their initial success in cancer into immunological and autoimmune diseases. The development of in vivo CAR-T approaches is also identified as a transformative innovation that could solve current scalability and accessibility issues.

This expansion opens up a massive new market for cell therapies and could revolutionize the treatment paradigm for numerous chronic and debilitating autoimmune conditions.

Get started free

Topics

J.P. Morgan Healthcare Conference Targeted Protein Degradation (TPD)Gene Editing Gene Writing CAR-T Cell Therapy Immunology Autoimmune Diseases Oncology CDMO Drug Delivery Viral Vectors Kymera Therapeutics Tessera Therapeutics Clinical Validation

Processed Apr 20, 2026 yt-dlp + mlx-whisper + Gemini